ArticleAmerican journal of hematology2021
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Open access · greenAbstract readComparative Study
In one paragraph
Article in American journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 7 pooled it
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 7 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Conventional therapy vs HMA or LDAC with or without venetoclax in older adults with AML: systematic review and meta-analysis.Blood advances · 2026Pooled it
- American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2026Guideline
- The efficacy and safety of venetoclax combined with decitabine in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Pooled it
- Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis.Annals of medicine · 2023Pooled it
- Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Trial
- Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.The Lancet. Haematology · 2022Trial
- Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.Blood advances · 2021Trial
- Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.British journal of haematology · 2026Article
- Review
- Efficacy and safety of venetoclax-based regimens versus intensive chemotherapy in older adults with newly diagnosed acute myeloid leukemia: a single-center retrospective study.International journal of hematology · 2026Article
- Article
- Article
- Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.Blood advances · 2025Review
- Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia.European journal of medical research · 2025Article
- Things (like AML salvage) go better with VEN(etoclax).Blood advances · 2025Article
- Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.Annals of hematology · 2025Article
- Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.Therapeutic advances in hematology · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 1 institution in 1 country.
Abhishek MaitiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9043-538X
Wei QiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-9140-0610
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tapan M KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-9892-9832
Elias J JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-4465-6119
Naval G DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-7103-373X
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-7679-6453
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-3631-2482
Sherry A PierceDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kathryn S MontalbanoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1670-6513
Kiran NaqviDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maro OhanianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1689-4470
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-2983-2738
Yesid AlvaradoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Musa YilmazDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4498-4895
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Steven M KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael AndreeffDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1144-1958
Prithviraj BoseDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4343-5712
Alessandra FerrajoliDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ghayas C IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lucia MasarovaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Philip A ThompsonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Caitlin R RauschDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4166-5717
Jing NingDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1908-3307
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9003-0390
Marina Y KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-9347-2212
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTargeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimenR01CA235622 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y, SPENCER, DAVID H · 2019 to 2024
$1.8MNCI NIH HHS CA016672NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA235622NIH HHS R01CA235622
Abstract
Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax compare to intensive chemotherapy (IC) in patients who are "fit" or "unfit" for IC. We compared outcomes of older patients with newly diagnosed AML receiving 10-day decitabine with venetoclax (DEC10-VEN) vs IC. DEC10-VEN consisted of daily venetoclax with decitabine 20 mg/m
Indexed as
AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicClinical Trials, Phase II as TopicCombined Modality TherapyConsolidation ChemotherapyCytarabineDecitabineDrug Administration ScheduleDrug EvaluationFemaleHematopoietic Stem Cell TransplantationHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicCytarabineDecitabineSulfonamidesvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.